Mazdutide
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Innovent · Phase 2 · Active, not recruiting · Enrollment 141
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| IBI362 4.0mg | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
| IBI362 6.0mg | n/r | n/r | n/r | n/r |
Not shown
- IBI362 4.0mg: endpoint not reported
- placebo: endpoint not reported
- IBI362 6.0mg: endpoint not reported